Guidelines on the management of in-patients with the new coronavirus infection (COVID-19)

Cover Page


Cite item

Full Text

Abstract

.

About the authors

A. V. Molochkov

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Author for correspondence.
Email: fake@neicon.ru
Доктор медицинских наук, профессор Russian Federation

S. A. Terpigorev

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук Russian Federation

A. V. Dreval

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук, профессор Russian Federation

D. E. Karateev

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук Russian Federation

A. V. Kildyushevsky

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук, профессор Russian Federation

D. A. Kulikov

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Кандидат медицинских наук, доцент Russian Federation

V. V. Likhvantsev

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук, профессор Russian Federation

A. M. Ovezov

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Доктор медицинских наук, доцент Russian Federation

E. Yu. Ogneva

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Кандидат медицинских наук Russian Federation

E. V. Smirnova

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Russian Federation

A. P. Faenko

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Кандидат медицинских наук Russian Federation

Zh. S. Filippovskaya

ГБУЗ МО МОНИКИ им. М.Ф. Владимирского

Email: fake@neicon.ru
Кандидат медицинских наук Russian Federation

References

  1. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon-p and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571—577. doi: 10.1099/vir.0.061911-0.
  2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 21 April 2020.
  3. TOFAcitinib in SARS-CoV2 Pneumonia. ClinicalTrials.gov Identifier: NCT04332042. Available at https://clinicaltrials.gov/ct2/show/NCT04332042#fireglass_params&tabid=aebc706216c4a74f&start_with_session_counter=3&application_server_address=pfizer3.prod.fire.glass. Accessed 21 April 2020.
  4. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6» (утв. Министерством здравоохранения РФ 28 апреля 2020 г.). [Электронный ресурс]. URL: https://base.garant.ru/73964533/
  5. Методические рекомендации ФАР «Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией (COVID-19)» (версия № 2 от 18 апреля 2020 года). [Электронный ресурс]. URL: http://www.far.org.ru/newsfar/496-metreccovid19
  6. Клинические рекомендации ФАР «Диагностика и интенсивная терапия острого респираторного дистресс-синдрома» (утв. президиумом ФАР 30 марта 2020 г.) [Электронный ресурс]. URL: http://www.far.org.ru/newsfar/479-recards
  7. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-2533. doi: 10.1001/jama.2012.5669.
  8. Hall JE. Guyton and Hall textbook of medical physiology. 13th ed. Saunders; 2015. 1168 p.
  9. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB; National Institutes of Health, National Heart, Lung, and Blood Institute ARDS Network. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007 Aug;132(2):410-417. doi: 10.1378/chest.07-0617.
  10. Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, Thompson BT, Brower RG; NIH/NHLBI PETAL Network Collaborators. Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute respiratory distress syndrome. Chest. 2016 Aug;150(2):307-313. doi: 10.1016/j.chest.2016.01.003.
  11. Lamia B, Chemla D, Richard C, Teboul JL. Clinical review: interpretation of arterial pressure wave in shock states. Crit Care. 2005;9(6):601-606. doi: 10.1186/cc3891.
  12. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod E, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 Apr 7:138745. doi: 10.1172/JCI138745. Epub ahead of print.
  13. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Stroher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015 Aug 15;61(4):496-502. doi: 10.1093/cid/civ334.
  14. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447-456. doi: 10.1093/cid/ciq106.
  15. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007 Oct 4;357(14):1450-1451. doi: 10.1056/NEJMc070359.
  16. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004 Sep;2(9):695-703. doi: 10.1038/nrmicro974.
  17. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Mar 27:e204783. doi: 10.1001/jama.2020.4783. Epub ahead of print.
  18. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020 Mar 31:S0012-3692(20)30571-7. doi: 10.1016/j.chest.2020.03.039.
  19. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 6:202004168. doi: 10.1073/pnas.2004168117. Epub ahead of print.
  20. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J, Ahn MY, Chin BS, Kim YS, Lee H, Yong D, Kim HO, Kim S, Choi JY. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.
  21. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25882. Epub ahead of print.
  22. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-46. doi: 10.1007/s10096-004-1271-9.
  23. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev. 2020 Feb 21. doi: 10.1016/j.tmrv.2020.02.003. Epub ahead of print.
  24. Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang. 2020 Apr 20. doi: 10.1111/vox.12937. Epub ahead of print.
  25. Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers. Transplantation. 2008 Dec 27;86(12):1666-1671. doi: 10.1097/TP.0b013e31818fe505.
  26. Bisaccia E, Berger C, Klainer AS. Extracorporeal photopheresis in the treatment of AIDS-related complex: a pilot study. Ann Intern Med. 1990 Aug 15;1 13(4):270-275. doi: 10.7326/0003-4819-113-4-270.
  27. Redfield DC, Richman DD, Oxman MN, Kronenberg LH. Psoralen inactivation of influenza and herpes simplex viruses and of virus-infected cells. Infect Immun. 1981 Jun;32(3):1216-1226.
  28. Duan SM, Zhao XS, Wen RF, Huang JJ, Pi GH, Zhang SX, Han J, Bi SL, Ruan L, Dong XP; SARS Research Team. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. Biomed Environ Sci. 2003 Sep;16(3):246-255.
  29. Darnell ME, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion. 2006 Oct;46(10):1770-1777. doi: 10.1111/j.1537-2995.2006.00976.x.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Molochkov A.V., Terpigorev S.A., Dreval A.V., Karateev D.E., Kildyushevsky A.V., Kulikov D.A., Likhvantsev V.V., Ovezov A.M., Ogneva E.Y., Smirnova E.V., Faenko A.P., Filippovskaya Z.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies